Riggs Asset Management’s Adicet Bio ACET Stock Holding History

Riggs Asset Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-70	Closed	-$685	–	123
2025 Q2	$685	Buy	+70	New	+$738	﹤0.01%	808

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Riggs Asset Management's ACET Position: Q3 2025 in Review

Riggs Asset Management sold out of Adicet Bio (ACET) in Q3 2025, closing a stake of 70 shares — an estimated $685 sold.

Riggs Asset Management first reported a position in ACET in Q2 2025 and held it in 1 quarter. The position peaked at $685 in Q2 2025. 54 funds tracked by Wall St. Rank hold ACET as of Q3 2025.

Riggs Asset Management reported no remaining Adicet Bio position as of Q3 2025 after selling out during the quarter.
Riggs Asset Management sold 70 Adicet Bio shares in Q3 2025, an estimated $685.
Riggs Asset Management first reported a position in Adicet Bio in Q2 2025 and held it in 1 quarter.
Riggs Asset Management's Adicet Bio position peaked at $685 in Q2 2025.
54 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.